Coronavirus News Roundup: October 17–October 23
Here are pandemic highlights for the week
Here are pandemic highlights for the week
An open letter
Neurological symptoms might arise from multiple causes. But does the virus even get into neurons?
Instead of shutting down whole cities, we can use big data to take a more targeted approach
In a case on the Affordable Care Act next month, a conservative court could take away protections for preexisting conditions
President Trump and other conspiracy fantasists touted the fake claim that COVID death counts are exaggerated. But three kinds of evidence point to more than 350,000 deaths*
The independent advisers to the CDC and FDA will not bend to politics
Here are pandemic highlights for the week
A vaccine made by Pfizer could seek emergency approval by the third week of November, but it likely won’t be available to the public until mid- to late 2021
Nirav Shah directs Maine’s response, which is seeing impressive results despite risk factors
Epidemiologists offer tips for U.S. voters and poll workers to limit their chances of getting infected
From a human-made virus to vaccine conspiracy theories, we rounded up the most insidious false claims about the pandemic
It’s not just “antiscience thinking”
Synthetic peptides that mimic human antibodies for COVID-19 could be cheaper and easier to produce
This “infodemic” has to stop
A stretch of Neandertal DNA has been associated with some cases of severe COVID-19, but it’s unclear how much of a risk it poses. Christopher Intagliata reports.
The pandemic offers colleges and universities an unexpected opportunity to reinvent themselves in ways that better serve students and faculty
Here are pandemic news highlights for the week
China has promised vaccines to many countries, but whether it can meet its commitments is unclear
Doctors say the president could be heading for a bad stretch in prolonged illness—or an upward path to recovery
You have free articles left.
Support our award-winning coverage of advances in science & technology.
Already a subscriber? Sign in.